Top-Rated Stocks NASDAQ:KRTX Karuna Therapeutics - KRTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $195.69 +3.54 (+1.84%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$189.45▼$196.1850-Day Range$189.25▼$236.8252-Week Range$92.26▼$278.25Volume225,182 shsAverage Volume266,107 shsMarket Capitalization$6.72 billionP/E RatioN/ADividend YieldN/APrice Target$262.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Karuna Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside34.3% Upside$262.75 Price TargetShort InterestBearish6.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 13 Articles This WeekInsider TradingSelling Shares$11.47 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($8.78) to ($9.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector635th out of 1,029 stocksPharmaceutical Preparations Industry312th out of 504 stocks 3.5 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $262.75, Karuna Therapeutics has a forecasted upside of 34.3% from its current price of $195.69.Amount of Analyst CoverageKaruna Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.01% of the float of Karuna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaruna Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Karuna Therapeutics has recently decreased by 2.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 3.3 News and Social Media Coverage News SentimentKaruna Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Karuna Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for KRTX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,467,250.00 in company stock.Percentage Held by Insiders16.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to decrease in the coming year, from ($8.78) to ($9.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -26.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -26.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 11.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Karuna Therapeutics (NASDAQ:KRTX) StockKaruna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.Read More Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KRTX Stock News HeadlinesFebruary 7, 2023 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Receives $262.75 Consensus Price Target from AnalystsFebruary 4, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Rating Reiterated by HC WainwrightFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…February 3, 2023 | finance.yahoo.comKaruna (KRTX) to Obtain Global Rights to Goldfinch's CandidatesFebruary 3, 2023 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Forecasted to Post Q1 2023 Earnings of ($2.92) Per ShareFebruary 3, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Karuna Therapeutics (KRTX)February 2, 2023 | finance.yahoo.comKaruna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product CandidatesJanuary 28, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Now Covered by Analysts at UBS GroupFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 27, 2023 | markets.businessinsider.comAnalyst Expectations for Karuna Therapeutics's FutureJanuary 17, 2023 | reuters.comKRTX.A - | Stock Price & Latest News | ReutersJanuary 10, 2023 | finance.yahoo.comKaruna Therapeutics sees broad possibilities for its novel schizophrenia drugJanuary 3, 2023 | finance.yahoo.comKaruna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 17, 2022 | finance.yahoo.comKaruna Therapeutics' (NASDAQ:KRTX) investors will be pleased with their stellar 144% return over the last three yearsDecember 9, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Karuna TherapeuticsDecember 9, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Karuna TherapeuticsDecember 8, 2022 | bizjournals.comThe Petri Dish: Gene therapy startup withdraws IPO plan; Capital One exec joins Moderna as CIODecember 7, 2022 | seekingalpha.comKaruna: Acquisition Prospects Thin With CEO ChangeDecember 6, 2022 | msn.comWhy Karuna Therapeutics Shares Are Trading Sharply LowerDecember 6, 2022 | seekingalpha.comKaruna Therapeutics drops 12% after CEO changeDecember 6, 2022 | marketwatch.comKaruna Therapeutics Replaces CEO As Paul Becomes Chief ScientistDecember 6, 2022 | seekingalpha.comKaruna Therapeutics appoints Bill Meury as CEO and PresidentDecember 6, 2022 | finance.yahoo.comKaruna Therapeutics Appoints Bill Meury as President and Chief Executive OfficerNovember 23, 2022 | msn.comLooking Into Karuna Therapeutics's Return On Capital EmployedNovember 16, 2022 | finance.yahoo.comBiotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The HelmNovember 6, 2022 | finance.yahoo.comEarnings Update: Karuna Therapeutics, Inc. (NASDAQ:KRTX) Just Reported And Analysts Are Boosting Their EstimatesNovember 3, 2022 | msn.comKaruna Therapeutics: Q3 Earnings InsightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KRTX Company Calendar Last Earnings11/04/2021Today2/07/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Forecast$262.75 High Stock Price Forecast$330.00 Low Stock Price Forecast$183.00 Forecasted Upside/Downside+34.3%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($7.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,800,000.00 Net MarginsN/A Pretax Margin-537.65% Return on Equity-35.85% Return on Assets-34.24% Debt Debt-to-Equity RatioN/A Current Ratio29.93 Quick Ratio29.93 Sales & Book Value Annual Sales$36.96 million Price / Sales181.92 Cash FlowN/A Price / Cash FlowN/A Book Value$16.95 per share Price / Book11.55Miscellaneous Outstanding Shares34,360,000Free Float28,796,000Market Cap$6.72 billion OptionableNot Optionable Beta1.18 Key ExecutivesAndrew MillerChief Operating OfficerTroy A. IgnelziChief Financial Officer & SecretaryStephen BrannanChief Medical OfficerRonald MarcusSenior Vice President-MedicalInder KaulVice President-Clinical DevelopmentKey CompetitorsElanco Animal HealthNYSE:ELANGrifolsNASDAQ:GRFSAscendis Pharma A/SNASDAQ:ASNDApellis PharmaceuticalsNASDAQ:APLSRoivant SciencesNASDAQ:ROIVView All CompetitorsInsiders & InstitutionsTD Asset Management IncBought 23,900 shares on 2/7/2023Ownership: 0.293%Envestnet Asset Management Inc.Bought 1,528 shares on 2/7/2023Ownership: 0.018%Oppenheimer Asset Management Inc.Bought 484 shares on 2/7/2023Ownership: 0.006%IFP Advisors IncBought 158 shares on 2/7/2023Ownership: 0.002%Cutler Group LLC CASold 1,500 shares on 2/7/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KRTX Stock - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRTX shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price forecast for 2023? 15 equities research analysts have issued 12-month target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $183.00 to $330.00. On average, they expect the company's share price to reach $262.75 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How have KRTX shares performed in 2023? Karuna Therapeutics' stock was trading at $196.50 at the beginning of the year. Since then, KRTX shares have decreased by 0.4% and is now trading at $195.69. View the best growth stocks for 2023 here. When is Karuna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our KRTX earnings forecast. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.47) by $0.25. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Karuna Therapeutics' stock symbol? Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX." Who are Karuna Therapeutics' major shareholders? Karuna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Clarius Group LLC (0.32%), Emerald Advisers LLC (0.29%), TD Asset Management Inc (0.29%), Emerald Mutual Fund Advisers Trust (0.23%), New York State Common Retirement Fund (0.20%) and Catalyst Private Wealth LLC (0.06%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi. View institutional ownership trends. How do I buy shares of Karuna Therapeutics? Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karuna Therapeutics' stock price today? One share of KRTX stock can currently be purchased for approximately $195.69. How much money does Karuna Therapeutics make? Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.72 billion and generates $36.96 million in revenue each year. The company earns $-143,800,000.00 in net income (profit) each year or ($7.44) on an earnings per share basis. How many employees does Karuna Therapeutics have? The company employs 118 workers across the globe. How can I contact Karuna Therapeutics? Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com. This page (NASDAQ:KRTX) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.